Table 1.
Summary of therapeutic trials in NSCLC and SCLC combining targeted therapy and/or chemotherapy with immunotherapy. This is a non-exhaustive list taken from ClinicalTrials.gov (with NCT identifier). Clinical trials concerning NSCLC (non small cell lung carcinoma) are indicated in the black box, and SCLC (Small cell lung carcinoma) in the red box. NSCLC: Non small cell lung carcinoma, aPD-L1: anti programmed death ligand 1, MTORi: mammalian target of rapamaycin inhibitors aPD-1: anti programmed cell death protein 1, VEGF(R) i: vascular endothelial growth factor (receptor) inhibitor, aCTLA-4: anti Cytotoxic T-lymphocyte antigen 4, TKi: tyrosine kinase inhibitor, MEKi: MAPK-ERK inhibitor, IDOi: indoleamine 2,3-DiOxygenase inhibitor, EGFRi: epidermal growth factor receptor inhibitor, BRAFi: B-raf inhibitor, NA: not applicable, SCLC: Small cell lung carcinoma, PARPi: Poly (ADP-ribose) polymerase inhibitor.
| NCT identifier | Phase | Tumor type | Immunotherapies | Targeted therapies | Chemotherapies |
|---|---|---|---|---|---|
| NCT04348292 | I | Resectable NSCLC | Durvalumab (a PD-L1) |
Sirolimus (MTORi) |
None |
| NCT03991819 | I | Advanced NSCLC | Pembrolizumab (a PD-1) |
Binimetinib (MEKi) |
None |
| NCT04507906 | I/II | Advanced NSCLC | Nivolumab (a PD-1) |
Anlotinib (VEGFRi) |
None |
| NCT03377023 | I/II | Advanced NSCLC | Nivolumab (a PD-1) Ipilimumab (a CTLA-4) |
Nintedanib (multiple TKi) |
None |
| NCT02658890 | I/II | Advanced NSCLC | Nivolumab (a PD-1) Ipilimumab (a CTLA-4) |
BMS-986205 (IDOi) | None |
| NCT03562871 | I/II | Advanced NSCLC | Pembrolizumab (a PD-1) |
IO102 (IDOi) | Carboplatin Pemetrexed |
| NCT03581487 | I/II | Advanced NSCLC | Durvalumab (a PD-L1) Tremelimumab (a CTLA-4) |
Selumetinib (MEKi) |
None |
| NCT03600701 | II | Advanced NSCLC | Atezolizumab (a PD-L1) |
Cobimetinib (MEKi) | None |
| NCT03689855 | II | Advanced NSCLC | Atezolizumab (a PD-L1) |
Ramucirumab (VEGFRi) | None |
| NCT03786692 | II | Advanced NSCLC | Atezolizumab (a PD-L1) |
Bevacizumab (VEGFi) | Carboplatin Pemetrexed |
| NCT04670913 | II | Advanced NSCLC | Camrelizumab (a PD-1) |
Apatinib (VEGFRi) | None |
| NCT03527108 | II | Advanced NSCLC | Nivolumab (a PD-1) |
Ramucirumab (VEGFRi) | None |
| NCT03971474 | II | Advanced NSCLC | Pembrolizumab (a PD-1) |
Ramucirumab (VEGFRi) |
None |
| NCT04340882 | II | Advanced NSCLC | Pembrolizumab (a PD-1) |
Ramucirumab (VEGFRi) |
Docetaxel |
| NCT04512430 | II | Resectable NSCLC EGFR mutated |
Atezolizumab (a PD-L1) |
Bevacizumab (VEGFi) |
Pemetrexed Carboplatin |
| NCT04517526 | II | Advanced NSCLC EGFR mutated |
Durvalumab (a PD-L1) |
Bevacizumab (VEGFi) |
Pemetrexed Cisplatin Carboplatin |
| NCT04120454 | II | Advanced NSCLC EGFR mutated |
Pembrolizumab (a PD-1) |
Ramucirumab (VEGFRi) |
None |
| NCT04989322 | II | Advanced NSCLC EGFR, ALK and ROS aberrations |
Pembrolizumab (a PD-1) |
Lenvatinib (multiple TKi) | Carboplatin Pemetrexed |
| NCT03178552 | II/III | Advanced NSCLC | Atezolizumab (a PD-L1) |
Bevacizumab (VEGFi) Vemurafenib (BRAFi) Cobimetinib (MEKi) |
Carboplatin Pemetrexed |
| NCT03976375 | III | Advanced NSCLC | Pembrolizumab (a PD-1) |
Lenvatinib (multiple TKi) |
None |
| NCT04973293 | NA | Resectable NSCLC | Sintilimab (a PD-1) |
Bevacizumab (VEGFi) |
Carboplatin Pemetrexed |
| NCT03830918 | I/II | Advanced SCLC | Atezolizumab (a PD-L1) |
Niraparib (PARPi) |
Temozolomide |
| NCT04728230 | I/II | Advanced SCLC | Durvalumab (a PD-L1) |
Olaparib (PARPi) |
Carboplatin Etoposide |